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Abstract:  Spinal and bulbar muscular atrophy (SBMA) is a hereditary motor neuron 
disease caused by the expansion of a polyglutamine tract in the androgen receptor (AR). 
The histopathological finding in SBMA is loss of lower motor neurons in the anterior horn 
of the spinal cord as well as in the brainstem motor nuclei. Animal studies have revealed 
that the pathogenesis of SBMA depends on the level of serum testosterone, and that 
androgen deprivation mitigates neurodegeneration through inhibition of nuclear 
accumulation of the pathogenic AR. Heat shock proteins, ubiquitin-proteasome system and 
transcriptional regulation are also potential targets of therapy development for SBMA.  
Keywords:  Spinal and bulbar muscular atrophy (SBMA); polyglutamine; androgen 
receptor (AR); leuprorelin acetate. 
 
 
1. Introduction 
 
Polyglutamine diseases are hereditary neurodegenerative disorders caused by an abnormal 
expansion of a trinucleotide CAG repeat, which encodes a polyglutamine tract. To date, nine 
polyglutamine diseases are known: Huntington’s disease (HD), spinal and bulbar muscular atrophy 
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(SBMA), dentatorubral-pallidoluysian atrophy (DRPLA) and six forms of spinocerebellar ataxia 
(SCA) (Table 1). SBMA, also known as Kennedy’s disease, is the first of the neurodegenerative 
diseases, for which the molecular basis was discovered to be the expansion of a trinucleotide CAG 
repeat in the gene of the causative gene.  
Table 1. Classification of polyglutamine diseases.  
Disease  Major clinical features  Affected regions 
Causative 
protein 
Gene 
(locus) 
Huntington's disease  
(HD) 
Chorea, cognitive deficits, 
psychiatric disturbances  
Striatum,  
cerebral cortex 
Huntingtin 
IT15 
(4p16.3) 
Spinal and bulbar 
muscular atrophy 
(SBMA) 
Weakness, muscular 
atrophy, bulbar palsy 
Spinal cord, 
brainstem 
Androgen 
receptor 
AR  
(Xq13-q12) 
Spinocerebellar ataxia 
type 1 (SCA1) 
Ataxia, bulbar palsy, 
pyramidal signs, muscular 
atrophy 
Cerebellum, 
brainstem 
Ataxin 1 
SCA1  
(6p23) 
Spinocerebellar ataxia 
type 2 (SCA2) 
Ataxia, slow eye 
movement, neuropathy 
Cerebellum, 
brainstem 
Ataxin 2 
SCA2 
(12q24.1) 
Spinocerebellar ataxia  
type 3 (SCA3, 
Machado-Joseph 
disease) 
Ataxia, bulging eye, 
parkinsonism, spasticity, 
fasciculations 
Cerebellum, basal 
ganglia, brainstem,  
spinal cord 
Ataxin 3 
SCA3/MJD
(14q32.1) 
Spinocerebellar ataxia 
type 6 (SCA6) 
Ataxia Cerebellum 
α1A-voltage-
dependent 
calcium 
channel subunit 
CACNA1A 
(19p13) 
Spinocerebellar ataxia 
type 7 (SCA7) 
Ataxia, retinal 
degeneration 
Cerebellum, retina, 
brainstem,  
visual cortex 
Ataxin 7 
SCA7 
(3p12-p13) 
Spinocerebellar ataxia 
type 17 (SCA17) 
Ataxia, cognitive deficits, 
dystonia, parkinsonism 
Cerebellum, striatum 
TATA box 
binding protein 
TBP 
(6q27) 
Dentatorubral-
pallidoluysian atrophy  
(DRPLA) 
Ataxia, myoclonic 
epilepsy,  
choreoathetosis, cognitive 
deficits 
Cerebellum, cerebral 
cortex, globus 
pallidus, red nuclei, 
subthalamic nuclei 
Atrophin 1 
DRPLA 
(12p13.31) 
2. Clinical and genetic features of SBMA 
In general, symptoms of polyglutamine diseases typically appear in mid-life and progressively 
deteriorate before death from fatal complications. Clinical features vary for each disorder, 
corresponding to the pathological distribution of neurodegeneration (Table 1). Int. J. Mol. Sci. 2009, 10                 
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Major symptoms of SBMA are weakness, atrophy and fasciculations of bulbar, facial and limb 
muscles [1]. Patients with SBMA occasionally demonstrate signs of androgen insensitivity such as 
gynecomastia, testicular atrophy, impaired erection and decreased fertility, some of which are detected 
before the onset of motor impairment. Female carriers are usually asymptomatic, but some express 
subclinical phenotypes including high amplitude motor unit potentials on electromyography. The 
progression of SBMA is usually slow, but life-threatening respiratory tract infection often occurs in the 
advanced stages of the disease, resulting in early death in some patients. The cardinal cause of death is 
aspiration pneumonia [2]. 
The molecular basis of SBMA is the expansion of a trinucleotide CAG repeat, which encodes the 
polyglutamine tract, in the first exon of the androgen receptor (AR) gene [3]. The CAG repeat within 
AR ranges in size from 11 to 35 in normal subjects, but from 40 to 62 in SBMA patients [3-5]. There is 
an inverse correlation between the CAG repeat size and the age at onset of motor impairments or the 
disease severity adjusted by the age at examination in SBMA [6,7] as well as in other polyglutamine 
diseases [8]. In a nerve conduction study of SBMA, the CAG repeat size and the age at onset were 
significantly different among the patients with motor- and sensory-dominant phenotypes, indicating 
that a longer CAG repeat is more closely linked to the motor-dominant phenotype and a shorter CAG 
repeat is more closely linked to the sensory-dominant phenotype [9]. 
3. Neuropathology and molecular mechanisms of SBMA 
The fundamental histopathological finding in SBMA is loss of lower motor neurons in the anterior 
horn of the spinal cord as well as in the brainstem motor nuclei except for the third, fourth and sixth 
cranial nerves [10]. The number of nerve fibers is reduced in the ventral spinal nerve root, reflecting 
motor neuronopathy. Sensory neurons in the dorsal root ganglia are less severely affected, and large 
myelinated fibers demonstrate a distally accentuated sensory axonopathy in the peripheral nervous 
system. Muscle histopathology includes both neurogenic and myogenic findings: there are groups of 
atrophic fibers with a number of small angular fibers, fiber type grouping and clamps of pyknotic 
nuclei as well as variability in fiber size, hypertrophic fibers, scattered basophilic regenerating fibers 
and central nuclei.  
In general, the abnormal polyglutamine protein forms inclusion bodies in affected neurons, which is 
a unifying histopathological hallmark of polyglutamine diseases [11]. These neuronal inclusion bodies 
are often detected in the nucleus, although they may be formed within the cytoplasm or neurites. The 
deposition of inclusion bodies is not only found in the postmortem neural tissues from patients, but has 
also been reported in animal models of polyglutamine diseases. The abnormal polyglutamine proteins 
in the inclusion bodies are often truncated, indicating that proteolytic cleavage appears to enhance the 
toxicity of the causative gene products [12]. The abnormal polyglutamine proteins are also expressed 
outside the nervous system, leading to non-neuronal pathology, such as diabetes mellitus, in some 
polyglutamine diseases [13,14]. 
In SBMA, nuclear inclusions (NIs) containing the pathogenic AR are found in the residual motor 
neurons in the brainstem and spinal cord as well as in non-neuronal tissues including the prostate, 
testes, and skin [15]. These inclusions are detectable using antibodies recognizing a small portion of 
the N-terminus of the AR protein, but not by those against the C-terminus of the protein. This Int. J. Mol. Sci. 2009, 10                 
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observation implies that the C-terminus of the AR is truncated or masked upon formation of NI. A full-
length AR protein with an expanded polyglutamine tract is cleaved by caspase-3, releasing a 
polyglutamine-containing toxic fragment, and the susceptibility to cleavage is polyglutamine repeat 
length-dependent [16]. Thus, proteolytic cleavage is likely to enhance the toxicity of the pathogenic 
AR protein. Electron microscopic immunohistochemistry shows dense aggregates of AR-positive 
granular material without limiting membrane, both in the neural and non-neural inclusions, in contrast 
to the other polyglutamine diseases where NIs take the form of filamentous structures.  
A number of studies have indicated that transcriptional dysregulation underlies the molecular 
mechanism of neuronal dysfunction in polyglutamine diseases. Transcriptional co-activators such as 
cAMP-response element binding protein-binding protein (CBP) have been shown to be sequestrated 
into the NIs through protein-protein interaction in mouse models and patients with SBMA [17]. It has 
also documented that the histone acetyltransferase activity of CBP is inhibited in animal models of 
polyglutamine diseases, and that histone acetylation level is decreased in a mouse model of SBMA 
[18]. Taken together, polyglutamine-mediated transcriptional dysregulation appears to play an 
important role in the pathogenesis of SBMA.  
Mitochondrial impairment and oxidative stress have also been stipulated as a causative molecular 
event in polyglutamine diseases. Depolarization of the mitochondrial membrane and an elevated level 
of reactive oxygen species have been observed in a cellular model of SBMA [19]. Moreover, the 
pathogenic AR protein represses the transcription of the subunits of peroxisome proliferator-activated 
receptor gamma coactivator-1 (PGC-1), a transcriptional co-activator that regulates the expression of 
various nuclear-encoded mitochondrial proteins [19]. Similar finding have been reported in cellular 
and animal models of polyglutamine diseases, suggesting that mitochondrial dysfunction is a unifying 
molecular mechanism whereby abnormal polyglutamine proteins induce neuronal damage. 
Obstruction of axonal transport has also gained attention as a cause of neuronal dysfunction in 
SBMA. The pathogenic AR has been shown to impair axonal transport through a pathway that 
involves activation of cJun N-terminal kinase (JNK) activity [20]. In a mouse model of SBMA, the 
nuclear accumulation of the abnormal AR protein induces transcriptional dysregulation of dynactin 1, 
an axonal motor protein that regulates axonal trafficking [21]. Given that a mutation in the dynactin 1 
gene has been shown to cause motor neuron degeneration mimicking SBMA, a disrupted axonal 
transport is a potential molecular basis for SBMA [22]. 
4. Protein folding abnormalities in SBMA 
Although NIs are a disease-specific histopathological finding, their role in pathogenesis has been 
heavily debated. Several studies have suggested that NIs may indicate a cellular response coping with 
the toxicity of abnormal polyglutamine protein [23]. Instead, the diffuse nuclear accumulation of the 
mutant protein has been considered essential for inducing neurodegeneration in polyglutamine diseases 
including SBMA (Figure 1). Recent data suggest that the toxic species of protein in polyglutamine 
diseases may be soluble mutant conformers, which can exist as oligomers or monomers containing 
beta-sheet conformation [24-26]. 
 Int. J. Mol. Sci. 2009, 10                 
 
 
1004
Figure 1. Accumulation of abnormal proteins in polyglutamine diseases. 
Immunohistochemistry of autopsy specimens from patients using an anti-polyglutamine 
antibody (1C2). (A) Cerebral cortex, HD; (B) Putamen, HD; (C) Dentate nucleus, DRPLA, 
(D) Globus pallidus, DRPLA; (E) Anterior horn of spinal cord, SBMA; (F) Pons, SBMA. 
Scale bar = 100 µm [27]. 
 
 
Although it is difficult to determine the toxic protein species in human histopathology, diffuse 
accumulation of the causative gene products has been construed as an important finding. An 
immunohistochemical study on autopsied SBMA patients using an anti-polyglutamine antibody 
demonstrated that diffuse nuclear accumulation of the pathogenic AR is more frequently observed than 
NIs in the anterior horn of the spinal cord [28]. Intriguingly, the frequency of diffuse nuclear 
accumulation of the pathogenic AR in spinal motor neurons strongly correlates with the length of the 
CAG repeat in the AR gene. No such correlation has been found between NI occurrence and the CAG 
repeat length. A similar observation has been reported in DRPLA [29]. Taken together, it appears that 
the pathogenic AR containing an elongated polyglutamine tract principally accumulates within the 
nuclei of motor neurons in a diffusible form, leading to neuronal dysfunction and eventual cell death in 
SBMA. In support of this hypothesis, neuronal dysfunction is halted by genetic modulation preventing 
nuclear import of the pathogenic polyglutamine-containing protein in cellular and animal models of 
polyglutamine diseases [8]. 
Since the human AR is widely expressed in various organs, nuclear accumulation of the pathogenic 
AR protein is detected not only in the central nervous system, but also in non-neuronal tissues such as 
scrotal skin. The degree of pathogenic AR accumulation in scrotal skin epithelial cells tends to be 
correlated with that in the spinal motor neurons in autopsy specimens, and it is well correlated with 
CAG repeat length and inversely correlated with the motor functional scale [30]. These findings 
indicate that scrotal skin biopsy with anti-polyglutamine immunostaining is a good biomarker with 
which to monitor SBMA pathogenic processes (Figure 2). Int. J. Mol. Sci. 2009, 10                 
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Figure 2. Mutant AR nuclear accumulation in scrotal skin and spinal motor neurons. (A) 
Mutant AR accumulation was remarkable in both spinal motor neurons and scrotal skin of 
Patient 1, but less remarkable in both motor neurons and skin in Patient 2. Scale bar = 30 
µm. (B) The extent of mutant AR accumulation in scrotal skin epithelial cells showed a 
tendency to correlate with that in anterior horn cells. 
 
5. Therapeutic strategies for SBMA 
For any given polyglutamine disease, more than one mechanism likely contributes to neuronal 
dysfunction and eventual cell death. They include: (i) misfolding of the disease protein resulting in 
altered function; (ii) deleterious protein interactions engaged in by the mutant protein; (iii) formation 
of toxic oligomeric complexes; (iv) transcriptional dysregulation; (v) mitochondrial dysfunction 
resulting in impaired bioenergetics and oxidative stress; (vi) impaired axonal transport; (vii) aberrant 
neuronal signaling including excitotoxicity; (viii) cellular protein homeostasis impairment; and (ix) 
RNA toxicity [31]. Although each of these molecular mechanisms could be subject to therapeutic 
interventions, upstream events are more plausible targets than secondary cellular changes. 
There is no well-established disease-modifying therapy for SBMA. Potential therapeutics, however, 
have emerged from basic research using animal models. Among these therapeutic approaches, 
androgen deprivation has been translated into clinic [27]. Anti-androgen therapies have been 
developed taking advantage of the fact that the accumulation of the pathogenic AR proteins is 
dependent on the circulating level of testosterone [32,33]. Surgical castration has been shown to 
reverse motor dysfunction in mouse models of SBMA [34]. The  luteinizing hormone-releasing 
hormone analogue, leuprorelin, prevents nuclear translocation of aberrant AR proteins, resulting in a 
significant improvement of disease phenotype in a mouse model of SBMA [35]. These results of 
animal studies were verified in a phase 2 clinical trial of leuprorelin, in which the patients treated with 
this drug exhibited decreased mutant AR accumulation in scrotal skin biopsy, significantly higher 
functional scores and better swallowing parameters than those receiving placebo (Figure 3). Autopsy 
of one patient who received leuprorelin suggested that androgen deprivation inhibits the nuclear 
accumulation and/or stabilization of mutant AR in the motor neurons of the spinal cord and brainstem Int. J. Mol. Sci. 2009, 10                 
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(Figure 4). These observations suggest that administration of leuprorelin suppresses the deterioration 
of neuromuscular impairment in SBMA by inhibiting the toxic accumulation of mutant AR [36]. 
Figure 3. Efficacy results of leuprorelin in SBMA patients. (A) The frequency of diffuse 
nuclear 1C2 staining (indicative of mutant AR) in the scrotal epithelial cells was 
significantly decreased after the 48-week administration of leuprorelin acetate. (B) 
Changes in the ALSFRS-R scores showed treatment duration-dependent improvements in 
the leuprorelin-treated groups. Scale bars = 50 µm. Data are expressed as means ± SEM. 
*p < 0.05; **p < 0.005; ***p < 0.001 with respect to Group D [36]. 
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Figure 4. Effects of leuprorelin acetate on nuclear accumulation of mutant AR. (A, B) The 
accumulation of mutant AR in neurons was remarkable both in the pontine base and in the 
spinal anterior horn of all the control, non-treated autopsied patients, but the number of 
1C2-positive neurons was relatively small in the leuprorelin-treated patient. Scale 
bars=100 µm. (C) Mutant AR accumulation in biopsied scrotal skin epithelial cells was 
markedly reduced by leuprorelin. Scale bars=50 µm. Data are expressed as means±SD [36]. 
 
 
Activation of the cellular defense machinery is another promising therapeutic approach for SBMA. 
Over-expression of heat shock proteins (HSPs), stress-inducible molecular chaperones, inhibits toxic 
accumulation of abnormal AR protein and suppresses neurodegeneration in a mouse model of SBMA Int. J. Mol. Sci. 2009, 10                 
 
 
1008
[37]. Similar beneficial effects have also been achieved by the pharmacological induction of HSPs 
[38]. On the other hand, inhibition of Hsp90 has been demonstrated to arrest neurodegeneration by 
activating the  ubiquitin-proteasome system in SBMA. Treatment with 17-allylamino geldanamycin 
(17-AAG), a potent Hsp90 inhibitor, dissociated p23 from the Hsp90-AR complex, and thus facilitated 
proteasomal degradation of the pathogenic AR in cellular and mouse models of SBMA [39, 40]. 
Similar effects were observed in the SBMA mice being treated with an oral Hsp 90 inhibitor, 17-
(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) [41]. 
Transcriptional dysregulation is another target for therapeutic intervention. Because suppression of 
histone deacetylase (HDAC) activities results in an  augmentation of histone acetylation and a 
subsequent restoration of gene transcription, HDAC inhibitors have been considered to be of 
therapeutic benefit in polyglutamine diseases [42]. Butyrate was the first HDAC inhibitor to be 
discovered, and the related compound, phenylbutyrate, has been successfully employed in 
experimental cancer therapy. Oral administration of sodium butyrate ameliorates the symptomatic and 
histopathological phenotypes of a mouse model of SBMA through upregulation of histone acetylation 
in nervous tissues [18]. This compound has also been shown to alleviate neurodegeneration in a mouse 
model of DRPLA [43]. In mouse models of HD, the  administration of HDAC inhibitors (sodium 
butyrate, suberoylanilide hydroxamic acid and phenylbutyrate) has been shown to alleviate 
polyglutamine toxicity and improve neuronal dysfunction [44-46]. 
5. Conclusions 
Although the genetics of polyglutamine diseases were discovered as an abnormal expansion of a 
trinucleotide CAG repeat, detailed mechanisms of the diseases including SBMA have not been fully 
elucidated. The clinical trial of leuprorelin acetate suggests that androgen deprivation inhibits the 
nuclear accumulation and/or stabilization of mutant AR in the motor neurons, and thereby stabilizes 
the disease progression in SBMA patients. Future research approaches have to determine the main 
mechanisms which contribute to neuronal dysfunction and eventual cell death in SBMA. 
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